Use of
Use of Anaerofustis stercorihominis in the prevention and/or treatment of metabolic diseases such as obesity, diabetes, atherosclerosis-related diseases, and cardiovascular diseases.
1. A method for treating a metabolic disease, said method comprising:
administering an Anaerofustis stercorihominis AM25-6 strain with a deposit number of GDMCC 60087 or a composition comprising the Anaerofustis stercorihominis AM25-6 strain with a deposit number of GDMCC 60087 to a subject in need thereof to treat the metabolic disease.
2. The method of claim 1 , wherein the Anaerofustis stercorihominis AM25-6 strain with a deposit number of GDMCC 60087 comprises a 16s rDNA having the nucleotide sequence of SEQ ID NO: 1.
3. The method of claim 1 , wherein the Anaerofustis stercorihominis AM25-6 strain with a deposit number of GDMCC 60087 or the composition is administered orally.
4. The method of claim 1 , wherein the subject comprises a human or a non-human mammal.
5. The method of claim 1 , wherein the metabolic disease comprises a lipid metabolism disease and an insulin metabolism disease.
6. The method of claim 1 , wherein the composition comprises: (a) a safe and effective amount of Anaerofustis stercorihominis AM25-6 strain with a deposit number of GDMCC 60087, and (b) a food acceptable or pharmaceutically acceptable carrier.
7. The method of claim 1 , wherein the composition comprises 1×10 −1 to 1×10 20 cfu/mL or cfu/g of Anaerofustis stercorihominis AM25-6 strain with a deposit number of GDMCC 60087 based on the total volume or total weight of the composition.
8. The method of claim 1 , wherein the composition further comprises probiotics and/or prebiotics.
9. The method of claim 1 , wherein the composition further comprises a substance capable of maintaining the vitality of Anaerofustis stercorihominis AM25-6 strain with a deposit number of GDMCC 60087.
10. The method of claim 1 , wherein the composition is selected from the group consisting of a food composition, a health care composition, a pharmaceutical composition, a beverage composition, a feed composition, or a combination thereof.
11. The method of claim 1 , wherein the Anaerofustis stercorihominis AM25-6 strain with a deposit number of GDMCC 60087 exhibits one or more activities selected from the group consisting of:
(i) reducing a blood glucose level in mammals;
(ii) ameliorating glucose intolerance in mammals;
(iii) ameliorating myocardial ischemia in mammals;
(iv) reducing a blood lipid level in mammals;
(v) reducing body weight of mammals; and
(vi) ameliorating vasculopathy in mammals.
12. The method of claim 1 , wherein the composition is in a unit dosage form and the composition in each unit dosage form is of a mass of 0.05 g to 5 g.
13. The method of claim 8 , wherein the probiotics are selected from the group consisting of Lactic acid bacteria, Bifidobacteria, Lactobacillus acidophilus or a combination thereof, and
the prebiotics are selected from the group consisting of fructooligosaccharide (FOS), galactooligosaccharide (GOS), xylooligosaccharide (XOS), lactosucrose (LACT), soybean oligosaccharides (SOS), Inulin oligosaccharide or a combination thereof.
14. The method of to claim 1 , wherein the administering step is in dosage of 0.01 to 5 g/50 kg body weight per day.
15. The method of claim 1 , wherein the metabolic disease is selected from the group consisting of obesity, diabetes, atherosclerosis-related diseases, cardiovascular disease, or a combination thereof.